Credit Suisse Ag Rain Therapeutics Inc. Transaction History

Credit Suisse Ag

  • $101 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$4.75 - $8.01 $85,462 - $144,115
17,992 Added 224900.0%
18,000 $88,000
Q2 2022

Aug 12, 2022
BUY
$2.21 - $5.56 $17 - $44
8 New
8 $0

Others Institutions Holding RAIN

# of Institutions
3
Shares Held
122K
Call Options Held
0
Put Options Held
0
View Full List

About Rain Therapeutics Inc.

RAIN Quotes by TradingView
  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email